Development and therapeutic impact of HDAC6-selective inhibitors

Biochemical Pharmacology

Volumn 84, Issue 6, 2012, Pages 756-765

  Dallavalle, Sabrina ^a   Pisano, Claudio ^b   Zunino, Franco ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Sigma Tau SpA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor therapy; Drug combinations; Drug design; HDAC inhibitors; Histone deacetilase 6

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ACETAMIDE DERIVATIVE; ACY 1215; APICIDIN; BELINOSTAT; DACINOSTAT; DEPSIPEPTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 6 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ISOXAZOLE; LB 589; NAPHTHOQUINONE; OXAMFLATIN; PACLITAXEL; PHENYLBUTYRIC ACID; QUISINOSTAT; ROMIDEPSIN; ST 3595; TACEDINALINE; THIOL DERIVATIVE; TRIAZOLE; TRICHOSTATIN A; TUBACIN; TUBASTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE ARREST; DRUG DESIGN; DRUG SELECTIVITY; ENZYME MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 84864961112     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.06.014     Document Type: Note

References (70)

1. K. Sadoul, C. Boyault, M. Pabion, and S. Khochbin Regulation of protein turnover by acetyltransferases and deacetylases Biochimie 90 2008 306 312
2. F.J. Dekker, and H.J. Haisma Histone acetyl transferases as emerging drug targets Drug Discovery Today 14 2009 942
3. P.A. Jones, and S.B. Baylin The epigenomics of cancer Cell 128 2007 683 692
4. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
5. G. Franci, M. Miceli, and L. Altucci Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer Epigenomics 2 2010 731 742
6. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784
7. S. Spange, T. Wagner, T. Heinzel, and O.H. Krämer Acetylation of non-histone proteins modulates cellular signalling at multiple levels Int J Biochem Cell Biol 41 2009 185 198
8. L. Wang, E.F. de Zoeten, M.I. Greene, and W.W. Hancock Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells Nat Rev Drug Discov 8 2009 969 981
9. S.S. Hook, A. Orian, S.M. Cowley, and R.N. Eisenman Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes Proc Natl Acad Sci USA 99 2002 13425 13430
10. O. Witt, H.E. Deubzer, T. Milde, and I. Oehme HDAC family: what are the cancer relevant targets Cancer Lett 277 2009 8 21
11. S. Spiegel, S. Milstien, and S. Grant Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy Oncogene 31 2012 537 551
12. M.A. Rivieccio, C. Brochier, D.E. Willis, B.A. Walker, M.A. D'Annibale, and K. McLaughlin HDAC6 is a target for protection and regeneration following injury in the nervous system Proc Natl Acad Sci USA 106 2009 19599 19604
13. A. Valenzuela-Fernández, J.R. Cabrero, J.M. Serrador, and F. Sánchez-Madrid HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions Trends Cell Biol 18 2008 291 297
14. G.I. Aldana-Masangkay, and K.M. Sakamoto The role of HDAC6 in cancer J Biomed Biotechnol 2011 2011 875824
15. C. Boyault, K. Sadoul, M. Pabion, and S. Khochbin HDAC6 at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination Oncogene 26 2007 5468 5476
16. X. Zhang, Z. Yuan, Y. Zhang, S. Yong, A. Salas-Burgos, and J. Koomen HDAC6 modulates cell motility by altering the acetylation level of cortactin Mol Cell 27 2007 197 213
17. S. Saji, M. Kawakami, S. Hayashi, N. Yoshida, M. Hirose, and S. Horiguchi Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Oncogene 24 2005 4531 4539
18. D. Kaluza, J. Kroll, S. Gesierich, T.P. Yao, R.A. Boon, and E. Hergenreider Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin EMBO J 30 2011 4142 4156
19. J. Ai, Y. Wang, J.A. Dar, J. Liu, L. Liu, and J.B. Nelson HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Mol Endocrinol 23 2009 1963 1972
20. Y. Kawaguchi, J.J. Kovacs, A. McLaurin, J.M. Vance, A. Ito, and T.P. Yao The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 115 2003 727 738
21. P. Perego, G. Cossa, V. Zuco, and F. Zunino Modulation of cell sensitivity to antitumor agents by targeting survival pathways Biochem Pharmacol 80 2010 1459 1465
22. J.H. Lee, M.L. Choy, L. Ngo, S.S. Foster, and P.A. Marks Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair Proc Natl Acad Sci USA 107 2010 14639 14644
23. R.W. Robey, A.R. Chakraborty, A. Basseville, V. Luchenko, J. Bahr, and Z. Zhan Histone deacetylase inhibitors: emerging mechanisms of resistance Mol Pharmacol 8 2011 2021 2031
24. K.V. Butler, and A.P. Kozikowski Chemical origins of isoform selectivity in histone deacetylase inhibitors Curr Pharm Des 14 2008 505 528
25. T. Suzuki Explorative study on isoform-selective histone deacetylase inhibitors Chem Pharm Bull 57 2009 897 906
26. J.R. Somoza, R.J. Skene, B.A. Kats, C. Mol, J.D. Ho, and A.J. Jennings Structural snapshots of human HDAC 8 provide insights into the class I histone deacetylases Structure 12 2004 1325 1334
27. D.F. Wang, O. Wiest, P. Helquist, H.Y. Lan-Hargest, and N.L. Wiech On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of hystone deacetylase inhibitors J Med Chem 47 2004 3409 3417
28. T.K. Nielsen, H. Christian, A. Dickmanns, A. Schwienhorst, and R. Ficner Crystal structure of a bacterial class 2 histone deacetylase homologue J Mol Biol 354 2005 107 120
29. A. Mai, S. Massa, R. Pezzi, S. Simeoni, D. Rotili, and A. Nebbioso Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (Aryloxopropenyl)pyrrolyl hydroxyamides J Med Chem 48 2005 3344 3353
30. K. KrennHrubec, B.L. Marshall, M. Hedglin, E. Verdin, and S.M. Ulrich Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors Bioorg Med Chem Lett 17 2007 2874 2878
31. S.J. Haggarty, K.M. Koeller, J.C. Wong, and C.M. Grozinger Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc Natl Acad Sci USA 100 2003 4389 4394
32. S.J. Haggarty, K.M. Koeller, J.C. Wong, R.A. Butcher, and S.I. Schreiber Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays Chem Biol 10 2003 383 396
33. T. Hideshima, J.E. Bradner, J. Wong, D. Chauhan, P. Richardson, and S.L. Schreiber Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci USA 102 2005 8567 8572
34. G. Estiu, E. Greenberg, C.B. Harrison, N.P. Kwiatkowski, R. Mazitschek, and J.E. Bradner Structural origin of selectivity in class II-selective histone deacetylase inhibitors J Med Chem 51 2008 2898 2906
35. S. Schafer, L. Saunders, E. Eliseeva, A. Velena, M. Jung, and A. Schwienhorst Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs) Bioorg Med Chem 16 2008 2011 2033
36. S. Schäfer, L. Saunders, S. Schlimme, V. Valkov, J.M. Wagner, and F. Kratz Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors ChemMedChem 4 2009 283 290
37. Y. Chen, M. Lopez-Sanchez, D.N. Savoy, D.D. Billadeau, G.S. Dow, and Kozikowski AP A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum J Med Chem 51 2008 3437 3448
38. A.P. Kozikowski, S. Tapadar, D.N. Luchini, K.H. Kim, and D.D. Billadeau Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6 J Med Chem 51 2008 4370 4373
39. D.V. Smil, S. Manku, Y.A. Chanigny, S. Leit, A. Wahhab, and T.P. Yan Novel HDAC6 isoform selective chiral small molecole histone deacetylase inhibitors Bioorg Med Chem Lett 19 2009 688 692
40. K.V. Butler, J. Kalin, C. Brochier, G. Vistoli, B. Langley, and A.P. Kozikowski Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J Am Chem Soc 132 2010 10842 10846
41. J.H. Kalin, K.V. Butler, T. Akimova, W.W. Hancock, and A.P. Kozikowski Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells J Med Chem 55 2012 639 651
42. S. Dallavalle, R. Cincinelli, R. Nannei, L. Merlini, G. Morini, and S. Penco Design, synthesis and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors Eur J Med Chem 44 2009 1900 1912
43. V. Zuco, M. De Cesare, R. Cincinelli, R. Nannei, C. Pisano, and N. Zaffaroni Synergistic antitumor effects of novel HDAC inhibitors and Paclitaxel in vitro and in vivo Plos One 6 2011 e29085
44. L. Auzzas, A. Larsson, R. Matera, A. Baraldi, B. Deschênes-Simard, and G. Giannini Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity J Med Chem 53 2010 8387 8399
45. 3β-tetrapeptides J Med Chem 52 2009 7836 7846
46. L. Santo, T. Hideshima, A.L. Kung, J. Tseng, D. Tamang, and M. Yang Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 119 2012 2579 2589
47. Y. Itoh, T. Suzuki, A. Kouketsu, N. Suzuki, S. Maeda, and M. Yoshida Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors J Med Chem 50 2007 5425 5438
48. T. Suzuki, A. Kouketsu, Y. Itoh, S. Hisakawa, S. Maeda, and M. Yoshida Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate J Med Chem 49 2006 4809 4812
49. P.K. Gupta, R.C. Reid, L. Liu, A.J. Lucke, S.A. Broomfield, and M.R. Andrews Inhibitors selective for HDAC6 in enzymes and cells Bioorg Med Chem Lett 20 2010 7067 7070
50. P. Jones, M.J. Bottomley, A. Carfí, O. Cecchetti, F. Ferrigno, and P.M. Lo Surdo 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors Bioorg Med Chem Lett 18 2008 3456 3461
51. R. Scarpelli, A. Di Marco, F. Ferrigno, R. Laufer, I. Marcucci, and E. Muraglia Studies of the metabolic stability in cells of 5-(Trifluoroacetyl) thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors Bioorg Med Chem Lett 18 2008 6078 6082
52. E. Muraglia, S. Altamura, D. Branca, O. Cecchetti, F. Ferrigno, and M.V. Orsale P.2-trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors Bioorg Med Chem Lett 18 2008 6083 6087
53. J.M. Ontoria, S. Altamura, A. Di Marco, F. Ferrigno, R. Laufer, and E. Muraglia Identification of novel selective and stable inhibitors of Class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer theraphy J Med Chem 52 2009 6782 6789
54. E.S. Inks, B.J. Josey, S.R. Jesinkey, and C.J. Chou A novel class of small molecole inhibitors of HDAC 6 Chem Biol 7 2012 3331 3339
55. A.P. Kozikowski, Y. Chen, A.M. Gaysin, D.N. Savoy, D.D. Billadeau, and K.H. Kim Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC nanomolar-potency inhibitors of pancreatic cancer cell growth ChemMedChem 3 2008 487 501
56. J.H. Kalin, H. Zhang, S. Gaudrel-Grosay, G. Vistoli, and A.P. Kozikowski Chiral mercaptoactamides display enantioselective inhibition of histone deacetylase 6 and exhibit neuroprotection in cortical neuron models of oxidative stress ChemMedChem 7 2012 425 439
57. A.P. Kozikowski, Y. Chen, A. Gaysin, B. Chen, M.A. D'Annibale, and C.M. Suto Functional differences in epigenetic modulators. Superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies J Med Chem 50 2007 3054 3061
58. J. Schemies, W. Sippl, and M. Jung Histone deacetylase inhibitors that target tubulin Cancer Lett 280 2009 222 232
59. Y. Zhang, B. Gilquin, S. Khochbin, and P. Matthias Two catalytic domains are required for protein deacetylation J Biol Chem 281 2006 2401 2404
60. H. Zou, Y. Wu, M. Navre, and B.C. Sang Characterization of the two catalytic domains in histone deacetylase 6 Biochem Biophys Res Commun 341 2006 45 50
61. P. Perego, V. Zuco, L. Gatti, and F. Zunino Sensitization of tumor cells by targeting histone deacetylases Biochem Pharmacol 83 2012 987 994
62. C. Giommarelli, V. Zuco, E. Favini, C. Pisano, F. Dal Piaz, and N. De Tommasi The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition Cell Mol Life Sci 67 2010 995 1004
63. R. Rao, W. Fiskus, Y. Yang, P. Lee, R. Joshi, and P. Fernandez HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 112 2008 1886 1893
64. H.M. Verheul, B. Salumbides, K. Van Erp, H. Hammers, D.Z. Qian, and T. Sanni Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors Clin Cancer Res 14 2008 3589 3597
65. L. Catley, E. Weisberg, T. Kiziltepe, Y.T. Tai, T. Hideshima, and P. Neri Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 2006 3441 3519
66. R.B. Parmigiani, W.S. Xu, G. Venta-Perez, H. Erdjument-Bromage, M. Yaneva, and P. Tempst HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation Proc Natl Acad Sci USA 105 2008 9633 9638
67. G. Li, H. Jiang, M. Chang, H. Xie, and L. Hu HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases J Neurol Sci 304 2011 1 8
68. N.A. Shein, and E. Shohami Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries Mol Med 17 2011 448 456
69. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 2009 5459 5468
70. K.T. Thurn, S. Thomas, A. Moore, and P.N. Munster Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Future Oncol 7 2011 263 283